Advanced search
1 file | 682.41 KB

Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast

(2013) HISTOPATHOLOGY. 63(4). p.520-533
Author
Organization
Abstract
Aims: The incidence of ductal carcinoma insitu (DCIS) has increased since the introduction of screening mammography. Recurrence prediction is still not accurate, and could be improved by identifying additional prognostic markers. Periductal stroma actively participates in early breast cancer progression. Therefore, the aim of this study was to explore the prognostic potential of stromal characteristics in DCIS. Methods and results: Histopathological features and hormone receptor/HER2 status were analysed in a first cohort of 65 cases of DCIS with a median follow-up of 112months. Cox regression analysis revealed that myxoid stromal architecture was significantly associated with increased ipsilateral locoregional recurrence (P=0.015). Next, we performed immunohistochemical screening of nine stromal proteins in a second cohort of 82 DCIS cases, and correlated their expression with stromal architecture. Because reduced stromal decorin expression correlated most strongly with myxoid stroma (P<0.001), it was selected for further analysis in the first cohort. Patients with reduced periductal decorin expression had a higher risk of recurrence (P=0.008). Furthermore, HER2 overexpression was significantly associated with invasive but not with in situ recurrence (P=0.007). Conclusions: Periductal myxoid stroma and reduced periductal decorin expression seem to be prognostic for overall ipsilateral locoregional recurrence in DCIS, whereas HER2 expression might be a more specific biomarker for invasive recurrence.
Keywords
decorin, ductal carcinoma insitu, DCIS, invasive recurrence, ipsilateral locoregional recurrence, myxoid stroma, prognostic biomarkers, protein expression, PATHOLOGISTS GUIDELINE RECOMMENDATIONS, LOCAL RECURRENCE, PROTEIN EXPRESSION, TUMOR RECURRENCES, AMERICAN-SOCIETY, CANCER, PROGRESSION, GROWTH, RISK

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 682.41 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Van Bockstal, Mieke, Kathleen Lambein, Olivier Gevaert, Olivier De Wever, Marleen Praet, Veronique Cocquyt, Rudy Van den Broecke, Geert Braems, Hannelore Denys, and Louis Libbrecht. 2013. “Stromal Architecture and Periductal Decorin Are Potential Prognostic Markers for Ipsilateral Locoregional Recurrence in Ductal Carcinoma in Situ of the Breast.” Histopathology 63 (4): 520–533.
APA
Van Bockstal, M., Lambein, K., Gevaert, O., De Wever, O., Praet, M., Cocquyt, V., Van den Broecke, R., et al. (2013). Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast. HISTOPATHOLOGY, 63(4), 520–533.
Vancouver
1.
Van Bockstal M, Lambein K, Gevaert O, De Wever O, Praet M, Cocquyt V, et al. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast. HISTOPATHOLOGY. 2013;63(4):520–33.
MLA
Van Bockstal, Mieke, Kathleen Lambein, Olivier Gevaert, et al. “Stromal Architecture and Periductal Decorin Are Potential Prognostic Markers for Ipsilateral Locoregional Recurrence in Ductal Carcinoma in Situ of the Breast.” HISTOPATHOLOGY 63.4 (2013): 520–533. Print.
@article{4221273,
  abstract     = {Aims: The incidence of ductal carcinoma insitu (DCIS) has increased since the introduction of screening mammography. Recurrence prediction is still not accurate, and could be improved by identifying additional prognostic markers. Periductal stroma actively participates in early breast cancer progression. Therefore, the aim of this study was to explore the prognostic potential of stromal characteristics in DCIS.
Methods and results: Histopathological features and hormone receptor/HER2 status were analysed in a first cohort of 65 cases of DCIS with a median follow-up of 112months. Cox regression analysis revealed that myxoid stromal architecture was significantly associated with increased ipsilateral locoregional recurrence (P=0.015). Next, we performed immunohistochemical screening of nine stromal proteins in a second cohort of 82 DCIS cases, and correlated their expression with stromal architecture. Because reduced stromal decorin expression correlated most strongly with myxoid stroma (P{\textlangle}0.001), it was selected for further analysis in the first cohort. Patients with reduced periductal decorin expression had a higher risk of recurrence (P=0.008). Furthermore, HER2 overexpression was significantly associated with invasive but not with in situ recurrence (P=0.007).
Conclusions: Periductal myxoid stroma and reduced periductal decorin expression seem to be prognostic for overall ipsilateral locoregional recurrence in DCIS, whereas HER2 expression might be a more specific biomarker for invasive recurrence.},
  author       = {Van Bockstal, Mieke and Lambein, Kathleen and Gevaert, Olivier and De Wever, Olivier and Praet, Marleen and Cocquyt, Veronique and Van den Broecke, Rudy and Braems, Geert and Denys, Hannelore and Libbrecht, Louis},
  issn         = {0309-0167},
  journal      = {HISTOPATHOLOGY},
  language     = {eng},
  number       = {4},
  pages        = {520--533},
  title        = {Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast},
  url          = {http://dx.doi.org/10.1111/his.12188},
  volume       = {63},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: